stoxline Quote Chart Rank Option Currency Glossary
Genprex, Inc. (GNPX)
2.21  0.04 (1.84%)    06-17 16:00
Open: 2.14
High: 2.26
Volume: 29,619
Pre. Close: 2.17
Low: 2.11
Market Cap: 5(M)
Technical analysis
2024-06-17 5:23:46 PM
Short term     
Mid term     
Targets 6-month :  3.88 1-year :  4.77
Resists First :  3.32 Second :  4.09
Pivot price 2.57
Supports First :  2.09 Second :  1.74
MAs MA(5) :  2.38 MA(20) :  2.5
MA(100) :  3.58 MA(250) :  11.98
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  8.3 D(3) :  14.6
RSI RSI(14): 41.3
52-week High :  42 Low :  2.08
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ GNPX ] has closed above bottom band by 21.2%. Bollinger Bands are 37.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.26 - 2.27 2.27 - 2.28
Low: 2.08 - 2.1 2.1 - 2.11
Close: 2.19 - 2.21 2.21 - 2.23
Company Description

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

Headline News

Thu, 30 May 2024
Genprex to Present at the 2024 BIO International Convention - BioSpace

Mon, 20 May 2024
GNPX Stock Earnings: Genprex Beats EPS for Q1 2024 - InvestorPlace

Mon, 13 May 2024
Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors - BioSpace

Wed, 08 May 2024
Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner - PR Newswire

Mon, 25 Mar 2024
H.C. Wainwright starts Genprex stock at Buy on cancer gene therapy By -

Tue, 19 Mar 2024
Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - PR Newswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 2 (M)
Shares Float 2 (M)
Held by Insiders 1.6 (%)
Held by Institutions 6.8 (%)
Shares Short 50 (K)
Shares Short P.Month 70 (K)
Stock Financials
EPS -18.81
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 4.98
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -108.7 %
Return on Equity (ttm) -207.9 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -14.8
Qtrly Earnings Growth 0 %
Operating Cash Flow -25 (M)
Levered Free Cash Flow -14 (M)
Stock Valuations
PE Ratio -0.12
PEG Ratio 0
Price to Book value 0.44
Price to Sales 0
Price to Cash Flow -0.19
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android